Gold Is Little Changed in New York

Source: Bloomberg, Pham-Duy Nguyen (12/22/10)

"Futures are headed for a 10th straight annual gain."

Gold futures were little changed after advancing 27% this year on demand for a haven from escalating European debt.

Investment in 10 leading exchange-traded funds backed by gold has climbed 18% this year. Futures reached an all- time high of $1,432.50 an ounce on Dec. 7 and are headed for a 10th straight annual gain. The International Monetary Fund said yesterday it concluded the planned sale of 403.3 metric tons, or 13% of its gold reserves.

"The gold market is expected to trade higher today," Tom Pawlicki, an analyst at MF Global Holdings Ltd. in Chicago, said in a report. "Support will come from the completion of the IMF's gold sales, a bullish year-end seasonal pattern and ongoing worries over European sovereign debt."

Gold futures for February fell $0.80 to $1,388 at 9:45 a.m. on the Comex in New York. The price climbed 1.3% in the past three sessions.

Investors may interpret the IMF sale "to be an indication of reduced supplies from the official sector," Pawlicki said.

Gold priced in euros reached a record on Dec. 7. The cost of insuring Greek debt jumped to a four-week high after Fitch Ratings warned it may cut the nation's credit rating to junk.

Silver futures for March delivery fell $0.039, or 0.1%, to $29.355 an ounce. Before today, the metal jumped 75% this year.

Palladium futures for March delivery rose $4.30, or 0.6%, to $757.35 an ounce on the New York Mercantile Exchange.

Platinum futures for April delivery climbed $3.90, or 0.2%, to $1,731 an ounce.

Before today, palladium surged 84% this year, and platinum was up 17%.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.